ReviewInternational journal of molecular sciences2023
Hepatorenal Syndrome-Novel Insights into Diagnostics and Treatment.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- Fetal Urinary Cystatin C, NGAL and Beta-2-Microglobulin as Predictors of Postnatal Renal Function Impairment and Death in Fetuses with Lower Urinary Tract Obstruction.Journal of clinical medicine · 2026Article
- Correlation between albumin-bilirubin score and comorbidity of cardiovascular disease and chronic kidney disease: insights from NHANES 2011-2018.European journal of medical research · 2026Article
- Development and validation of a risk prediction model for hepatorenal syndrome in hepatic failure patients based on glucose-6-phosphate dehydrogenase and hepatic and renal function biochemical parameters.Journal of medical biochemistry · 2026Article
- Association of the fibrosis-4 index with early-stage cardiovascular-kidney-metabolic syndrome in a longitudinal community-based cohort.Frontiers in public health · 2026Article
- The Kidney in the Shadow of Cirrhosis: A Critical Review of Renal Failure.Biomedicines · 2025Review
- Correlation of Serum Zinc Levels with Hepatic Encephalopathy Severity in Patients with Decompensated Liver Cirrhosis: A Prospective Observational Study from Egypt.Biological trace element research · 2025Observational
- Life after hepatorenal syndrome: unraveling quality of life, psychological distress, and treatment preferences.BMC palliative care · 2025Article
- Hepato-Renal Crosstalk in Acute and Chronic Disease: From Shared Pathways to Therapeutic Targets.Biomedicines · 2025Review
- Targeting Metabolism: Innovative Therapies for MASLD Unveiled.International journal of molecular sciences · 2025Review
- Hepatorenal syndrome: Paving a pathway from a fatal condition to an opportunity to preserve kidney function.World journal of nephrology · 2025Article
- From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework.Biomolecules · 2025Review
- The Hepato-Cardio-Renal Axis in Cirrhosis: Hemodynamic and Mechanistic Insights, Diagnostic Biomarkers, and Expanding Therapeutic Horizons.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatorenal syndrome (HRS) is a disorder associated with cirrhosis and renal impairment, with portal hypertension as its major underlying cause. Moreover, HRS is the third most common cause of acute kidney injury, thus creating a major public health concern. This review summarizes the available information on the pathophysiological implications of HRS. We discuss pathogenesis associated with HRS. Mechanisms such as dysfunction of the circulatory system, bacterial infection, inflammation, impaired renal autoregulation, circulatory, and others, which have been identified as critical pathways for development of HRS, have become easier to diagnose in recent years. Additionally, relatively recently, renal dysfunction biomarkers have been found indicating renal injury, which are involved in the pathophysiology of HRS. This review also summarizes the available information on the management of HRS, focusing on vasoconstrictive drugs, renal replacement therapy, and liver transplant together with currently being investigated novel therapies. Analyzing new discoveries for the underlying causes of this condition assists the general research to improve understanding of the mechanism of pathophysiology and thus prevention of HRS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.